top of page
Reaching a new summit for the medical treatment of neurological disorders
Next-Gen Pharma
Next-Gen
Pharma
We focus our research in transforming biomedical sciences knowledge into fast-acting and controlled-release novel drugs.
Our tailored drug delivery systems targets specific therapeutic indications that go beyond mental health conditions.
Biomind Labs is developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders.
This unique approach targets the original and initial drivers of the diseases.
R&D to
change
lives.
Our commitment is to provide patients and the psychiatric community with novel pharmaceuticals that provide a comfortable, safe and efficient use.
19 patents applications derived from 8 priority documents PCT and EPO Written Opinions (ISR/WO): Very promising
19
-
(USPTO) United States Patent and Trademark Office
-
(PCT) Patent Cooperation Treaty
-
(EPO) European Patent Office
Across every stage of the molecule to market lifecycle.
A Robust IP Strategy
Our academic & corporate credentials
Elevating Healthcare Standards
Chief Executive Officer & Director
Alejandro Antalich
Chief Financial Officer & Director
Oscar León
Chief Scientific Officer
Paola Díaz Dellavalle
Chief Legal Officer
Juan Presa
Clinical Advisor
Martín Bruno
Head of Quality Assurance and Regulatory Affairs
Martín Daners
Scientific Laboratory Manager
Lucía Minini
Biomolecular Research Scientist
Florencia Ferraro
Chairman of the Board
Ravi Sood
Director
Dr. Ben Illigens
An experienced Board and Management with diverse public company experience, life sciences domain expertise form the Department of Neurology at Harvard Medical School and proven experience working with psychotropic substances in several jurisdictions and negotiating with government authorities and health agencies.
Our highly qualified team of scientists with more than fifteen years of experience in research, development, and management in life sciences projects, aim to go beyond behavioural studies and work on elucidating the biochemical and neurological mechanisms of our portfolio of molecules.
We are developing:
01
A unique portfolio of molecules, aimed to offer patients access to cost-effective and cutting-edge psychiatric treatments.
02
The most diversified pipeline of clinical trials targeting multiple diseases to seek fast-track approvals and breakthrough therapy designations for novel pharmaceuticals.
03
Complex products, on-demand products, and customised products, controlling the time and place of drug release for the specific needs of each patient.
04
A personalized medicine and a sustainable production to provide a democratic access to our novel pharmaceuticals regardless the income level of patients.
Newsroom
Biomind and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System
September 27, 2022
Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression
September 21, 2022
Biomind Labs Appoints Former FDA Director Dr. Thomas Laughren as Medical Advisor for Clinical Trials
July 27, 2022
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Depression & Anxiety in Alzheimer’s Disease
May 26, 2022
bottom of page